Media-Insert Communications

Media-Insert Communications

The blog of Media-Insert Communications – featuring freelance P.R. and journalism links to the work of Graham A. Jarvis.

Editing, Journalism, Copywriting, and Public Relations

Category: Pharmaceuticals

  • “As a company, we believe it can accelerate the critical path of discovery of a cure, and good outcomes for COVID-19 researchers and as a British Company, Bridgeworks already has a widely published track record with significant international reach.”

  • WAN data acceleration, also known as WAN Acceleration, is the only way to mitigate the effects of latency and packet loss in any meaningful way. Traditionally, the answer has been to move data centres or disaster recovery sites closer to each other to reduce latency. However, if they are within the same circles of disruption…

  • The race is on to find a #vaccine to #Coronavirus COVID-19. Bridgeworks has joined the effort. Bridgeworks offers its PORTrockIT products to qualifying organisations over the next twelve months, at no cost.

  • David Trossell, CEO and CTO of Bridgeworks, argues hyperconverged systems have many benefits to the smaller healthcare providers. “By consolidating down multiple technologies from multiple providers for all the separate equipment that forms a modern data centre, along with all the differing support contracts and possible iteroparity issues that can occur, hyperconverged brings this all…

  • Could big data be the key to curing cancer? Many people have been lost to cancer, and everybody can potentially get one form of cancer or another. The race is therefore on to find a cure. Increasingly, pharmaceutical companies and organisations conducting research to push cancer into history realise that the answer may lie in…

  • Having spent a month out in the open after making public its desire to buy the British drugmaker, Pfizer was unable to clear enough hurdles to push the deal through. Concern that the transaction was merely a tax mitigation exercise certainly didn’t help matters, while AstraZeneca’s board was stubborn in its call for a higher…